Werewolf Therapeutics, Inc. (HOWL)
| Market Cap | 149.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -114.82M |
| Shares Out | 27.65M |
| EPS (ttm) | -4.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,093 |
| Open | 5.78 |
| Previous Close | 5.79 |
| Day's Range | 5.20 - 5.82 |
| 52-Week Range | 3.42 - 19.72 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 17.34 (+221.1%) |
| Earnings Date | Aug 11, 2022 |
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditional... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for HOWL stock is "Buy." The 12-month stock price forecast is 17.34, which is an increase of 221.11% from the latest price.
News
Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
WATERTOWN, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
- Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613; received $15.0M upfront payment and eligibility for up to $1.26B in downstr...
JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?
Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Mee...
WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ: HOWL) WTX-613. WTX-613 is a differentiated, conditi...
Jazz, Werewolf sign licensing deal worth up to $1.2 billion
Shares of Werewolf Therapeutics Inc. jumped 10.8% in premarket trading on Thursday after the company announced a licensing deal with Jazz Pharmaceuticals Plc worth up to $1.2 billion. Jazz now has exclu...
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Devel...
Werewolf to receive $15 million upfront payment, with potential for up to $1.26 billion in development, regulatory and sales milestone payments in addition to royalties on future net sales WTX-613 expan...
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights
-Closed upsized IPO in May 2021 raising $120 million in gross proceeds-
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering I...
CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condi...
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condi...
Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...
Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...
Werewolf Therapeutics Added to the Nasdaq Biotechnology Index
CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...
Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (...
Data demonstrates the strength of Werewolf's innovative therapeutic approach across multiple conditionally activated pipeline programs Data demonstrates the strength of Werewolf's innovative therapeutic...
Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
-Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program-
Werewolf Therapeutics to Present at Upcoming Conferences in November 2021
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics...
Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors
Over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities Over 30 years of ...
Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer ...
Posters Detail Preclinical Data on the Company's WTX-124 and WTX-330 Molecules for the Potential Treatment of Cancer Posters Detail Preclinical Data on the Company's WTX-124 and WTX-330 Molecules for th...
Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic...
Werewolf Therapeutics Inks Solid Tumor Trial Collaboration With Merck
Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate WTX-124 in combination with Keytruda (pembrolizu...
Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program
Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination with KEYTRUDA® (pembrolizumab) as a treatment for pati...
Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update
CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...
4 Global IPO Stocks Outperforming the S&P 500 Over the Past Month
In light of the global initial public offering market recording its strongest second quarter in two decades by volume and proceeds, four stocks that had their IPO during the past three months and outper...